BRPI0517058A - agonistas e antagonistas do receptor acoplado à proteìna g e métodos de uso - Google Patents
agonistas e antagonistas do receptor acoplado à proteìna g e métodos de usoInfo
- Publication number
- BRPI0517058A BRPI0517058A BRPI0517058-3A BRPI0517058A BRPI0517058A BR PI0517058 A BRPI0517058 A BR PI0517058A BR PI0517058 A BRPI0517058 A BR PI0517058A BR PI0517058 A BRPI0517058 A BR PI0517058A
- Authority
- BR
- Brazil
- Prior art keywords
- antagonists
- protein
- methods
- receptor agonists
- coupled receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
Abstract
AGONISTAS E ANTAGONISTAS DO RECEPTOR ACOPLADO à PROTEìNA G E MéTODOS DE USO. A presente invenção relata de um modo geral receptores acoplados à proteína G (GPCRs) e, em particular, agonistas e antagonistas GPCR, uso destes compostos e de suas composições farmacêuticas, como por exemplo, no tratamento, modulação e/ou prevenção de condições fisiológicas asociadas a GPCRs, tais como no tratamento de condições nas quais receptores de quimiocina fazem parte, por exemplo, sépsis, artrite, inflamação e doenças autoimunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62570604P | 2004-11-04 | 2004-11-04 | |
PCT/US2005/039959 WO2006052723A2 (en) | 2004-11-04 | 2005-11-04 | G protein coupled receptor agonists and antagonists and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517058A true BRPI0517058A (pt) | 2008-09-30 |
Family
ID=36337020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517058-3A BRPI0517058A (pt) | 2004-11-04 | 2005-11-04 | agonistas e antagonistas do receptor acoplado à proteìna g e métodos de uso |
Country Status (10)
Country | Link |
---|---|
US (1) | US8440627B2 (pt) |
EP (2) | EP2380904A1 (pt) |
JP (2) | JP2008519039A (pt) |
CN (1) | CN101094866A (pt) |
AU (2) | AU2005304963C1 (pt) |
BR (1) | BRPI0517058A (pt) |
CA (1) | CA2586344C (pt) |
IL (1) | IL182947A0 (pt) |
RU (1) | RU2430113C2 (pt) |
WO (1) | WO2006052723A2 (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8440627B2 (en) | 2004-11-04 | 2013-05-14 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2348047A1 (en) | 2000-04-21 | 2011-07-27 | New England Medical Center | G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
KR20070058455A (ko) | 2004-08-13 | 2007-06-08 | 프래시스 파마슈티컬즈 인코포레이티드 | 스핑고신-1-포스페이트(s1p) 수용체 활성을 조절하기위한 방법 및 조성물 |
TW200714610A (en) | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
EP2078036A2 (en) | 2006-10-31 | 2009-07-15 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Smoothened polypeptides and methods of use |
US20080213252A1 (en) * | 2007-01-03 | 2008-09-04 | Ethan Lerner | Methods of treating itch |
EP2362779A4 (en) * | 2008-11-04 | 2013-03-20 | Anchor Therapeutics Inc | CXCR4 RECEPTOR COMPOUNDS |
US20110301087A1 (en) * | 2008-11-04 | 2011-12-08 | Mcbride Edward | Crf1 receptor compounds |
CN103396474A (zh) * | 2008-11-04 | 2013-11-20 | 安科治疗公司 | Apj受体化合物 |
US20110300167A1 (en) * | 2008-11-04 | 2011-12-08 | Mcmurry Thomas J | Cxcr5 receptor compounds |
WO2010132954A1 (en) * | 2009-05-21 | 2010-11-25 | Oral Health Australia Pty Ltd | Method of treating periodontal disease by administering antagonists of par-2 |
EP2488210A4 (en) | 2009-10-12 | 2014-04-30 | Smith Holdings Llc | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS |
EP2566494B1 (en) * | 2010-02-26 | 2017-11-29 | Acer Therapeutics, Inc. | Cxcr4 receptor compounds |
EP2365011A1 (de) | 2010-03-02 | 2011-09-14 | Sika Technology AG | Aminogruppen - terminierter Schlagzähigkeitsmodifikator und dessen Verwendungen in Epoxidharzzusammensetzungen |
US10913781B2 (en) | 2011-04-08 | 2021-02-09 | Tufts Medical Center, Inc. | Pepducin design and use |
US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
ES2688081T3 (es) * | 2011-06-13 | 2018-10-30 | Tla Targeted Immunotherapies Ab | Tratamiento de dolencias asociadas a septicemia |
EP2726498A4 (en) * | 2011-06-28 | 2015-01-14 | Univ Rochester | PHOTOACTIVABLE RECEPTORS AND USES THEREOF |
US10766928B2 (en) | 2012-10-05 | 2020-09-08 | The University Of Kansas | Targeted conformationally-constrained kinked endosomal disrupting peptides |
US9701715B2 (en) * | 2012-10-05 | 2017-07-11 | The University Of Kansas | Conformationally-constrained kinked endosomal-disrupting peptides |
JP2016520570A (ja) | 2013-04-22 | 2016-07-14 | アンスティテュ ナシオナル ドゥ ラ ルシェルシュ アグロノミックInstitut National De La Recherche Agronomique | A型インフルエンザウイルス感染の治療又は予防に使用するためのpar−4アンタゴニスト |
CN104277106B (zh) * | 2013-07-03 | 2018-04-20 | 深圳大学 | 基于g蛋白偶联受体的哺乳动物细胞定向引导方法 |
US9855283B2 (en) | 2013-08-26 | 2018-01-02 | Shaperon Inc. | Composition comprising GPCR19 agonist as an active ingredient for preventing or treating allergic dermatitis |
KR101548955B1 (ko) | 2013-08-26 | 2015-09-02 | (주)샤페론 | Gpcr19 작용제를 유효성분으로 함유하는 아토피 예방 또는 치료용 조성물 |
KR101494275B1 (ko) * | 2013-08-26 | 2015-02-24 | 서울대학교기술지주 주식회사 | Gpcr19 경로의 활성화에 의한 골수 유래 면역 조절 세포 및 면역 조절 b 림프구의 체내외 증폭 |
FR3014693B1 (fr) * | 2013-12-16 | 2016-01-08 | Pf Medicament | Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
US10426815B2 (en) | 2015-01-20 | 2019-10-01 | The General Hospital Corporation | Prevention and treatment of itch with an MRGPR antagonist |
US11571462B2 (en) | 2015-06-03 | 2023-02-07 | The Medical College Of Wisconsin, Inc. | Engineered CCL20 locked dimer polypeptide |
CA2988086C (en) | 2015-06-03 | 2023-09-19 | The Medical College Of Wisconsin, Inc. | An engineered ccl20 locked dimer polypeptide |
EP3374386B1 (en) | 2015-11-13 | 2024-05-29 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
US10849955B2 (en) | 2016-09-28 | 2020-12-01 | City Of Hope | Methods of treating pancreatic cancer using GPCR antagonists |
UA125757C2 (uk) * | 2017-03-16 | 2022-06-01 | Медімм'Юн Лімітед | Антитіло до par2 і його застосування |
CN107903326B (zh) * | 2018-01-02 | 2020-06-30 | 广东省人民医院(广东省医学科学院) | 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物 |
WO2019236607A1 (en) * | 2018-06-04 | 2019-12-12 | Duke University | Compositions and methods for treating pain, inflammation, infection, malaria, and sepsis |
CN110806488B (zh) * | 2019-12-06 | 2020-09-25 | 南京医科大学 | Drd5及其激动剂在制备治疗炎症性疾病的药物中的应用 |
CN114195858B (zh) * | 2021-11-17 | 2023-09-08 | 罗赣 | 多肽及其改造体和在制备抗炎杀菌药物中的应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
NZ240921A (en) | 1990-12-12 | 1994-06-27 | Zymogenetics Inc | G protein coupled glutamate receptor (neurotransmitters), recombinant production |
US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
US5508384A (en) * | 1992-09-10 | 1996-04-16 | New York University | Polypeptide derived from a popamine receptor, and compositions and methods thereof |
US5750370A (en) * | 1995-06-06 | 1998-05-12 | Human Genome Sciences, Inc. | Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor |
AU2728297A (en) | 1996-04-15 | 1997-11-07 | Board Of Trustees Of The Leland Stanford Junior University | Soluble 7-transmembrane domain G-protein-coupled receptor compositions and me thods |
US5874245A (en) | 1996-05-16 | 1999-02-23 | Takeda Chemical Industries, Ltd. | Human G-protein coupled receptor (HIBCD07) |
US5935936A (en) * | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
AU3705097A (en) | 1996-07-01 | 1998-01-21 | Biosignal Inc. | Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization |
US6403305B1 (en) | 1997-02-06 | 2002-06-11 | Cornell Research Foundation, Inc. | Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor |
SE9702002D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
DE69937822T2 (de) | 1998-02-27 | 2009-01-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | G-protein-gekoppelte rezeptor-antagonisten |
US6071719A (en) | 1998-03-11 | 2000-06-06 | Smithkline Beecham Corporation | DNA encoding ECR 673: A 7-transmembrane G-protein coupled receptor |
US6111075A (en) | 1998-04-01 | 2000-08-29 | Zymogenetics, Inc. | Protese-activated receptor PAR4 (ZCHEMR2) |
GB9811692D0 (en) | 1998-06-01 | 1998-07-29 | Medical Res Council | Improvements in or relating to uptake of substances by cells |
US7304127B2 (en) * | 1999-08-27 | 2007-12-04 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use |
EP2348047A1 (en) | 2000-04-21 | 2011-07-27 | New England Medical Center | G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
SE0201863D0 (en) * | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
WO2006052723A2 (en) | 2004-11-04 | 2006-05-18 | New England Medical Center Hospitals, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
-
2005
- 2005-11-04 WO PCT/US2005/039959 patent/WO2006052723A2/en active Application Filing
- 2005-11-04 RU RU2007120594/10A patent/RU2430113C2/ru not_active IP Right Cessation
- 2005-11-04 BR BRPI0517058-3A patent/BRPI0517058A/pt not_active IP Right Cessation
- 2005-11-04 CN CNA2005800458273A patent/CN101094866A/zh active Pending
- 2005-11-04 EP EP11172012A patent/EP2380904A1/en not_active Withdrawn
- 2005-11-04 US US11/667,042 patent/US8440627B2/en active Active
- 2005-11-04 CA CA2586344A patent/CA2586344C/en not_active Expired - Fee Related
- 2005-11-04 EP EP05818166A patent/EP1814911A2/en not_active Withdrawn
- 2005-11-04 JP JP2007540067A patent/JP2008519039A/ja active Pending
- 2005-11-04 AU AU2005304963A patent/AU2005304963C1/en not_active Ceased
-
2007
- 2007-05-03 IL IL182947A patent/IL182947A0/en unknown
-
2010
- 2010-06-04 AU AU2010202328A patent/AU2010202328B2/en not_active Ceased
-
2012
- 2012-06-14 JP JP2012135250A patent/JP2012176985A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8440627B2 (en) | 2004-11-04 | 2013-05-14 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
Also Published As
Publication number | Publication date |
---|---|
AU2005304963C1 (en) | 2011-01-06 |
JP2012176985A (ja) | 2012-09-13 |
US8440627B2 (en) | 2013-05-14 |
IL182947A0 (en) | 2007-08-19 |
AU2005304963B2 (en) | 2010-03-04 |
AU2010202328B2 (en) | 2012-12-13 |
WO2006052723A3 (en) | 2006-09-08 |
JP2008519039A (ja) | 2008-06-05 |
WO2006052723A2 (en) | 2006-05-18 |
CN101094866A (zh) | 2007-12-26 |
US20080214451A1 (en) | 2008-09-04 |
CA2586344C (en) | 2013-05-28 |
RU2007120594A (ru) | 2008-12-10 |
EP2380904A1 (en) | 2011-10-26 |
EP1814911A2 (en) | 2007-08-08 |
CA2586344A1 (en) | 2006-05-18 |
RU2430113C2 (ru) | 2011-09-27 |
AU2005304963A1 (en) | 2006-05-18 |
AU2010202328A1 (en) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517058A (pt) | agonistas e antagonistas do receptor acoplado à proteìna g e métodos de uso | |
BR112012028707A2 (pt) | composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo. | |
WO2008036273A3 (en) | Receptor family profiling | |
CY1112456T1 (el) | Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6 | |
EA201100546A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
RS63204A (en) | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin | |
CL2011000975A1 (es) | Anticuerpo o fragmento del mismo que se une a al menos un residuo de animoacido del receptor tipo toll 3 (tlr3); composicion farmaceutica que lo comprende; su uso para tratar una condicion inflamatoria. | |
WO2008106429A3 (en) | Methods and compositions for the treatment of heart failure and other disorders | |
UY27469A1 (es) | Poplipéptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagón y sus métodos de uso farmacológico | |
CR20120393A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
CL2009000171A1 (es) | Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion. | |
NO20093064L (no) | Templatfikserte peptidhermere | |
CO6280470A2 (es) | Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina | |
TW200730168A (en) | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | |
Wang | The sequence signature of an Ig-fold | |
Gabriele et al. | Angiotensin II Type 1 receptor knockdown impairs interleukin‐1β‐Induced cytokines in human periodontal fibroblasts | |
Kokko et al. | In vitro analysis of stable, receptor-selective neurotensin [8− 13] analogues | |
WO2003046147A3 (en) | Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof | |
BRPI0707560B8 (pt) | combinação de análogos de somatostatina com seletividade diferente para subtipos de receptores de somatostatina humana, seu uso, composição farmacêutica, e embalagem comercial | |
WO2002102839A3 (en) | Novel g-protein coupled receptors and dna sequences thereof | |
CL2007003503A1 (es) | Compuestos derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea | |
WO2007038444A3 (en) | N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators | |
Beeton | KCa1. 1 channels as therapeutic targets for rheumatoid arthritis | |
MX2013003816A (es) | Combinaciones nuevas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: TUFTS MEDICAL CENTER, INC. (US) Free format text: ALTERADO DE: NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013. |